- Conditions
- Peyronie's Disease
- Interventions
- Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH), Penile Plication Surgery, Incision and Grafting (I&G) Surgery, RestoreX Penile Traction Device
- Drug · Procedure · Device
- Lead sponsor
- Charitable Union for the Research and Education of Peyronie's Disease
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Orem, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 361–384
of 995
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Crohn's Disease
- Interventions
- SHR0302, Placebos
- Drug
- Lead sponsor
- Reistone Biopharma Company Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 6
- States / cities
- Clearwater, Florida • Lake Wales, Florida • Tampa, Florida + 3 more
- Conditions
- Macular Degeneration
- Interventions
- 0.5 mg ranibizumab
- Drug
- Lead sponsor
- Charles C Wykoff, PhD, MD
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 4
- States / cities
- West Columbia, South Carolina • Houston, Texas • Katy, Texas + 1 more
- Conditions
- Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Interventions
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 918 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
- Conditions
- Healthy Adults, Mechanical Ventilation Dependence, Hypoxia, Exercise Training, Exercise Intolerance, Dietary Supplement, Nitrate Supplementation, Inspiratory Muscle Training
- Interventions
- Respiratory Muscle Training (RMT), Sham Respiratory Muscle Training, Dietary Supplement: Beetroot Juice Concentrate, placebo beverage
- Device · Dietary Supplement
- Lead sponsor
- Embry-Riddle Aeronautical University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Lintuzumab (SGN-33), Low dose cytarabine, Placebo
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 20
- States / cities
- Mobile, Alabama • Beverly Hills, California • Glendale, California + 16 more
- Conditions
- Asthma
- Interventions
- In-home asthma management program (AMP) provided by nurses, In-home asthma management program (AMP) provided by respiratory therapists
- Behavioral
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium + olodaterol, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 21
- States / cities
- Andalusia, Alabama • Jasper, Alabama • Brandon, Florida + 18 more
- Conditions
- Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
- Interventions
- Injectable extended-release buprenorphine, Sublingual buprenorphine-naloxone
- Drug
- Lead sponsor
- Yih-Ing Hser
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 7
- States / cities
- El Dorado, Arkansas • Garberville, California • Gibson City, Illinois + 4 more
- Conditions
- Metastatic Neuroendocrine Tumor
- Interventions
- Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Triapine
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 25
- States / cities
- Duarte, California • Irvine, California • Orange, California + 19 more
- Conditions
- Chronic Kidney Disease Stage 3
- Interventions
- AION-301, Placebo
- Biological · Drug
- Lead sponsor
- AION Healthspan, Inc.
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Miami, Florida
- Conditions
- Cigarette Smoking Among Patients Currently Receiving Methadone or Buprenorphine Treatment for Opioid Dependence
- Interventions
- incentive-based contingency management
- Behavioral
- Lead sponsor
- University of Vermont Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- H7-Coil, H1-Coil
- Device
- Lead sponsor
- Brainsway
- Industry
- Eligibility
- 22 Years to 68 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 7
- States / cities
- La Jolla, California • Los Angeles, California • Juno Beach, Florida + 4 more
- Conditions
- Fibrostenotic Crohn's Disease
- Interventions
- Ontunisertib, Placebo
- Drug
- Lead sponsor
- Agomab Spain S.L.U.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- Sun City, Arizona • Bradenton, Florida • Albany, New York + 4 more
- Conditions
- Cannabis Use, Delinquency
- Interventions
- Brief Family Based Intervention, Parenting Psychoeducation
- Behavioral
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 12 Years to 16 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Dry Eye Disease
- Interventions
- Lifitegrast, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Artesia, California + 33 more
- Conditions
- Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Bevacizumab, Cetuximab, Irinotecan, Laboratory Biomarker Analysis, Placebo
- Biological · Drug · Other
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Boise, Idaho • Sioux City, Iowa + 10 more
- Conditions
- Sleep Disturbance, Autism Spectrum Disorder
- Interventions
- Modified Sleep and Circadian Intervention, Enhanced Usual Care
- Behavioral
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Sleep, Psychological Stress
- Interventions
- Sleeping Healthy/Living Healthy, Attention Control
- Behavioral
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Interstitial Lung Disease
- Interventions
- ILD, Healthy, Pneumonia
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 635 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- olodaterol, tiotropium
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 7,903 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 117
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Florence, Alabama + 100 more
- Conditions
- Kerato Conjunctivitis Sicca
- Interventions
- KPI-121 Ophthalmic Suspension, Vehicle
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 901 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 64 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- 100mg SPN-812, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 48 Months to 69 Months
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 54
- States / cities
- Saraland, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 49 more
- Conditions
- Thromboembolism
- Interventions
- IWPC adapted genotype-guided dosing algorithm for warfarin, Modified IWPC genetic-guided warfarin dosing algorithm, Standard of care treatment
- Genetic · Other
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah